Eyestem raises $6.4 million in Series A funding from Biological E, Alkem, others
Eyestem, a Bengaluru-based cell therapy startup, has secured $6.4 million (Rs 51 crore) in a Series A round-headed by three pharma giants: Biological E Limited (BE), Alkem, NATCO, and Kemwell Biopharma entrepreneurs Anurag and Karan Bagaria. Endiya Partners and Kotak Private Equity, both existing investors, also participated in the financing round, valuing Eyestem at $46.4 million (Rs 371 crore) post-money.
“We created Eyestem with the express objective of being able to produce cell therapy solutions at scale for diseases that destroy a substantial amount of people in India and throughout the world,” stated Dr. Jogin Desai, Founder, and CEO of Eyestem. The backing of big Indian pharmaceutical firms that share our goal validates our strategy of generating inexpensive innovation for patients all around the world. Post this financing, we will stay engaged in strengthening our cell treatment platform and advancing our flagship product for Dry AMD through initial clinical trials of global standards.”
“We are extremely glad to be involved with Eyestem for its innovative work that serves unmet requirements of patients that have a substantial impact on quality of life,” stated Rajeev Nannapaneni, CEO of NATCO Pharma Limited. “Endiya Partners is happy to sponsor such strong, internationally competitive creative firms and participate in the current financing round,” stated Dr. Ramesh Byrapaneni, Managing Partner of Endiya Partners. The inclusion of renowned pharma and biotech investors to our capitalization table is a fantastic endorsement of the world-class research that Eyestem is conducting, which has the potential to impact millions of lives across the world.”
Eyestem was founded in 2016 by skilled professionals of clinical research, regenerative medicine, and ophthalmology experts. It is advised by a board of directors and has established collaborations with several other leaders in associated scientific disciplines in India, the United Kingdom, Japan, and the United States. Long-term goals include developing a scalable cell therapy platform to cure incurable diseases and democratizing worldwide access to these newer technologies.
Eyestem Research seems to be an interesting startup with a persuading development on biotechnology research platform. This startup would continue to prosper in the future. Wishing this startup good luck in all its future endeavors.Shishir Gupta, Founder and CEO, StartupLanes
Don’t keep wondering about funding, you can also raise funds. Learn how to raise funds here: Yes I want to raise funds.
If you are an emerging startup and are looking for investors to raise funds, StartupLanes has its own angel network and investment banking services and is connected to angel investors and VCs in 15 countries that ensure that our member startups have easy access to external funds to scale up constantly.
You can subscribe to our news posts by entering your email in the box on the right side of this page.
Check out our YouTube channel for insightful content from the Indian startup ecosystem.
Or join our Whatsapp group to interact with other founders: Yes, I want to join the Whatsapp group.
The right investment is key to beating inflation and growing your wealth. Do you wish to become an angel investor? Yes, I want to be an angel investor.
Are you a startup and facing challenges in your business? Do you want to grow your business? It is not as difficult as it sounds. Learn how to grow your business here- Yes, I want to grow my business.